1
|
Charles H, Fátima CV, Lucio V, María KA, Johar C, Kevin P, Luz BV, Guido GA, Eduarda BC, Sebastian MN, Heber QJ, Matilde QY, Karla ZV, Liesbeth HF, Javier RE, Juan SR, Antonio BO. Differences in SARS-COV-2 seroprevalence in the population of Cusco, Peru. GLOBAL EPIDEMIOLOGY 2024; 7:100131. [PMID: 38188037 PMCID: PMC10767270 DOI: 10.1016/j.gloepi.2023.100131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2023] [Revised: 11/22/2023] [Accepted: 11/27/2023] [Indexed: 01/09/2024] Open
Abstract
Background The spread of the coronavirus disease 2019 (COVID-19) in Peru has been reported at the regional level, few studies have evaluated its spread at the provincial level, in which the mechanisms could be different. Methods We conducted an analytical, cross-sectional, multistage observational population study to assess the seroprevalence of SARS-COV-2 at the provincial and urban/rural levels in a high-altitude setting. The sampling unit was the household, including a randomly selected family member. Sampling was performed using a data collection sheet on clinical and epidemiological variables. Chemiluminescence tests were used to detect total anti-SARS-COV-2 antibodies (IgG and IgM simultaneously). The percentages were adjusted to the sampling design. Results The overall prevalence in the region of Cusco was 25.9%, with considerably different prevalence between the 13 provinces (from 15.9% in Acomayo to 40.1% in Canchis) and between rural (21.1%) and urban (31.7%) areas. In multivariable model, living in a rural area was a protective factor (adjusted prevalence ratio [aPR], 0.68; 95% confidence interval [CI], 0.61-0.76). Conclusions Geographic diversity and population density determine different prevalence rates, typically lower in rural areas, possibly due to natural social distancing or limited interaction with people at risk.
Collapse
Affiliation(s)
| | - Concha-Velasco Fátima
- Dirección de Epidemiología e Investigación - Gerencia Regional de Salud del Cusco, Cusco, Peru
- Universidad Continental, Cusco, Peru
| | - Velásquez Lucio
- Universidad Andina del Cusco, Cusco, Peru
- Unidad de Epidemiología, Hospital Nacional Adolfo Guevara Velasco, Cusco, Peru
| | - K. Antich María
- Dirección de Epidemiología e Investigación - Gerencia Regional de Salud del Cusco, Cusco, Peru
- Universidad Peruana Cayetano Heredia, Lima, Peru
| | - Cassa Johar
- Dirección de Epidemiología e Investigación - Gerencia Regional de Salud del Cusco, Cusco, Peru
- Universidad Nacional San Antonio Abad del Cusco, Cusco, Peru
| | - Palacios Kevin
- Dirección de Epidemiología e Investigación - Gerencia Regional de Salud del Cusco, Cusco, Peru
| | | | | | | | | | - Quispe-Jihuallanca Heber
- Dirección de Inteligencia Sanitaria, Red de Servicios de Salud de Canas Canchis Espinar, Cusco, Peru
| | - Quispe-Yana Matilde
- Dirección de Inteligencia Sanitaria, Red de Servicios de La Convención, Cusco, Peru
| | - Zavala-Vargas Karla
- Dirección de Inteligencia Sanitaria – Gerencia Regional de Salud Cusco, Peru
| | | | | | | | | |
Collapse
|
2
|
Pons MJ, Mayanga-Herrera A, Palomino-Kobayashi LA, Quispe AM, Ugarte-Gil MF. High Anti-Interferon-Alpha Autoantibody Levels in Severe/Critical COVID-19 Patients from Peru. J Interferon Cytokine Res 2023; 43:565-570. [PMID: 37906115 DOI: 10.1089/jir.2023.0087] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2023] Open
Abstract
Innate immune responses through the production of type I interferon-α (anti-IFN-α) play an essential role in the defense against viruses. The autoantibodies (auto-Abs) anti-IFN-α are implicated in COVID-19 pathogenesis with higher levels among patients with worse prognoses. The study aimed to assess the levels of anti-IFN-α auto-Abs in Peruvian patients with severe/critical hospitalized COVID-19 compared to asymptomatic/mild COVID-19 outpatients and healthy controls. We analyzed 101 serum samples, including 56 (55.5%) severe/critical, 13 (12.3%) asymptomatic/mild COVID-19 patients, and 32 (32.2%) healthy controls, which we tested using a commercial ELISA anti-IFN-α-auto-Abs kit. We observed seropositivity of 48.2% (26/54) to anti-IFN-α auto-Abs among the severe/critical COVID-19 group, but 0% (0/13) and 3.1% (1/32) among the asymptomatic/mild COVID-19 and healthy groups (P = 0.021), respectively. Furthermore, we observed a significant association between the log10 of anti-IFN-α auto-Abs and the COVID-19 status, with the log10 of anti-IFN-α auto-Abs levels being significantly higher among the severe/critical COVID-19 group compared to the healthy controls (β = 1.20; confidence interval [95% CI]: 0.72-1.67; P < 0.001). Such association remains significant either when adjusted by age and gender (adjusted β = 1.16; 95% CI: 0.62-1.70; P < 0.001) and when adjusted by the subjects' age, gender, and obesity (adjusted β = 1.16; 95% CI: 0.62-1.70; P < 0.001). Despite not measuring neutralizing activity, this study highlights the high frequency of these auto-Abs in the Peruvian population with a worse prognosis of COVID-19.
Collapse
Affiliation(s)
- Maria J Pons
- Grupo de Enfermedades Infecciosas Re-Emergentes, Universidad Científica del Sur, Lima, Perú
| | - Ana Mayanga-Herrera
- Laboratorio de Cultivo Celular e Inmunología, Universidad Científica del Sur, Lima, Perú
| | | | - Antonio M Quispe
- Dirección de Investigación, Universidad Continental, Huancayo, Perú
| | - Manuel F Ugarte-Gil
- Reumathology, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru
- Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica Del Sur, Lima, Perú
| |
Collapse
|
3
|
Schwalb A, Armyra E, Méndez-Aranda M, Ugarte-Gil C. COVID-19 in Latin America and the Caribbean: Two years of the pandemic. J Intern Med 2022; 292:409-427. [PMID: 35411985 PMCID: PMC9115176 DOI: 10.1111/joim.13499] [Citation(s) in RCA: 25] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Worldwide, nations have struggled during the coronavirus disease 2019 (COVID-19) pandemic. However, Latin America and the Caribbean faced an unmatched catastrophic toll. As of March 2022, the region has reported approximately 15% of cases and 28% of deaths worldwide. Considering the relatively late arrival of SARS-CoV-2, several factors in the region were determinants of the humanitarian crisis that ensued. Pandemic unpreparedness, fragile healthcare systems, forthright inequalities, and poor governmental support facilitated the spread of the virus throughout the region. Moreover, reliance on repurposed and ineffective drugs such as hydroxychloroquine and ivermectin-to treat or prevent COVID-19-was publicised through misinformation and created a false sense of security and poor adherence to social distancing measures. While there were hopes that herd immunity could be achieved after the region's disastrous first peak, the emergence of the Gamma, Lambda, and Mu variants made this unattainable. This review explores how Latin America and the Caribbean fared during the first 2 years of the pandemic, and how, despite all the challenges, the region became a global leader in COVID-19 vaccination, with 63% of its population fully vaccinated.
Collapse
Affiliation(s)
- Alvaro Schwalb
- Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.,London School of Hygiene and Tropical Medicine, London, UK
| | - Eleonora Armyra
- Health Innovation Lab, Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru
| | - Melissa Méndez-Aranda
- Facultad de Ciencias y Filosofía, Laboratorio de Investigación en Enfermedades Infecciosas, Universidad Peruana Cayetano Heredia, Lima, Peru
| | - César Ugarte-Gil
- Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.,London School of Hygiene and Tropical Medicine, London, UK.,School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru
| |
Collapse
|